News & Views
Shire Expands Presence in Ophthalmology
May 26 2013
Shire plc has acquired SARcode Bioscience Inc, a privately held biopharmaceutical company in the ophthalmology therapeutic category along with global rights to its phase 3 compound LIFITEGRAST, which is currently under development for the signs and symptoms of dry eye disease. Shire anticipates launch of the product in the United States as early as 2016 pending a positive outcome of the phase 3 clinical development program and regulatory approvals. Shire is expecting to evaluate an appropriate regulatory filing strategy for markets outside of the United States. Terms included an upfront payment of $160 million, with SARcode shareholders eligible to receive additional undisclosed payments upon achievement of certain clinical, regulatory, and/or commercial milestones.
In its Q1 financial statement (May 2), Shire’s newly appointed CEO Flemming Ornskov said: “In the first quarter we added to our pipeline with three acquisitions: Lotus Tissue Repair, Premacure and SARcode BioSciences. The last two provide us with the foundation to build a potential new business unit in ophthalmology – a growing market with many unmet patient needs. We’re reviewing our pipeline to prioritise investment in our innovative, late stage pipeline assets. We also aim to focus our business development on acquiring later stage assets and to grow our sales in Latin America and Asia.
The global ophthalmic pharmaceutical market, was said to be valued at approximately $13 billion in 2012 with a compound annual growth rate of 4.5 %.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Microbiology Society Annual Conference 2024
Apr 08 2024 Edinburgh 2024
Apr 09 2024 Munich, Germany
Apr 10 2024 Helsinki, Finland
Analytica Anacon India & IndiaLabExpo
Apr 15 2024 Mumbai, India
Apr 16 2024 Moscow, Russia